<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583722</url>
  </required_header>
  <id_info>
    <org_study_id>0048-18-RMB</org_study_id>
    <nct_id>NCT04583722</nct_id>
  </id_info>
  <brief_title>Evaluating Astaxanthin Bioavailability, and a New Technology for Improving it, Using Natural Food Materials Only</brief_title>
  <official_title>Clinical Evaluation of a New Encapsulation Technology for Improving Astaxanthin Bioavailability Based on Natural Food Ingredients Only</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yoav D. Livney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Israel Innovation Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technion, Israel Institute of Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to develop a potato protein (PP)-based delivery system for&#xD;
      increasing oral bioavailability of lipophilic bioactives (nutraceuticals and drugs), using&#xD;
      astxanthin (AX) as a model, and to evaluate the system in vivo in a crossover clinical study&#xD;
      in human volunteers. Three different formulations were prepared, encapsulating AX oleoresin&#xD;
      (AXO) with (1) PP only, (2) PP+lecithin (LEC), and (3) PP+olive oil (OO). In a randomized,&#xD;
      double-blind, crossover study in human subjects, the PP-OO-AX formulation had a 4.8-fold&#xD;
      higher median plasma AX area under the concentration-over time curve (AUC; P&lt;0.001) compared&#xD;
      to the raw AXO formulation.&#xD;
&#xD;
      In conclusion, a non-allergenic, vegan, PP based delivery system made of &quot;all-natural&#xD;
      ingredients&quot; offers a great promise for increasing oral bioavailability of lipophilic&#xD;
      bioactives such as AX, for the enrichment of food and for dietary supplements, or oral&#xD;
      delivery of lipophilic drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Astaxanthin (AX) is a red xanthophyll carotenoid found mainly in algae (notably Haematococcus&#xD;
      Pluvialis microalga) and marine animals. AX is a stronger antioxidant than vitamin E and&#xD;
      β-carotene but has very low oral bioavailability. The purpose of this study was to develop a&#xD;
      potato protein (PP)-based delivery system for increasing oral bioavailability of lipophilic&#xD;
      bioactives (nutraceuticals and drugs), using AX as a model, and to evaluate the system in&#xD;
      vitro and in vivo in a crossover clinical study in human volunteers. Three different&#xD;
      formulations were prepared, encapsulating AX oleoresin (AXO) with (1) PP only, (2)&#xD;
      PP+lecithin (LEC), and (3) PP+olive oil (OO). The average particle diameters after&#xD;
      preparation were 0.29, 0.29, and 1.76 μm, and after freeze-drying and reconstitution 0.17,&#xD;
      0.07, and 6.93 μm, respectively. In vitro bioaccessibility was 33, 47, and 69%, respectively,&#xD;
      versus 16% only for the raw AXO. In a randomized, double-blind, crossover study in human&#xD;
      subjects, the PP-OO-AX formulation had a 4.8-fold higher median plasma AX area under the&#xD;
      concentration-over time curve (AUC; P&lt;0.001) compared to the raw AXO formulation. In&#xD;
      conclusion, a non-allergenic, vegan, PP based delivery system made of &quot;all-natural&#xD;
      ingredients&quot; offers a great promise for increasing oral bioavailability of lipophilic&#xD;
      bioactives such as AX, for the enrichment of food and for dietary supplements, or oral&#xD;
      delivery of lipophilic drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Actual">January 16, 2019</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma AX AUC</measure>
    <time_frame>1 year</time_frame>
    <description>Plasma AX AUC of 13 participants after consuming either the microencapsulated AX or the reference AX oleoresin, measured during 72 hrs post-ingestion, in a cross over study.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>AX oleoresin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Raw AX oleoresin, 15 mg AX (in 4 pululan capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AX-olive oil-PP emulsion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microencapsulated AX (1%:2%:3% (AXO:OO:PP, %w/v ratio) + 0.15% maltodextrin). 15 mg AX (in 4 pululan capsules)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AX-olive oil-PP emulsion</intervention_name>
    <description>single dose and plasma samples</description>
    <arm_group_label>AX oleoresin</arm_group_label>
    <arm_group_label>AX-olive oil-PP emulsion</arm_group_label>
    <other_name>(control- raw AXoleoresin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers&#xD;
&#xD;
          -  Aged 18 - 26&#xD;
&#xD;
          -  Normal physical examination&#xD;
&#xD;
          -  Normal electrocardiogram (E.C.G.)&#xD;
&#xD;
          -  Normal laboratory profile&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any active medical illness (e.g. liver disease, kidney disease, or diabetes,&#xD;
             intestinal malabsorption, hypercalcemia)&#xD;
&#xD;
          -  Lactose intolerance&#xD;
&#xD;
          -  Food allergies&#xD;
&#xD;
          -  Excessive alcohol use (over 40 ml/day)&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Hyperlipidemia (LDL&gt;130, triglycerides&gt;200)&#xD;
&#xD;
          -  Regular medication use&#xD;
&#xD;
          -  Obesity (BMI&gt;30 kg/m2)&#xD;
&#xD;
          -  Use of multivitamins, or carotenoid supplements during the past month prior to the&#xD;
             study&#xD;
&#xD;
          -  Current smoking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Segal, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrine Institute, Rambam Health Care Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Health Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.33218/001c.16781</url>
    <description>The publication reporting the clinical study</description>
  </link>
  <reference>
    <citation>Abuhassira-Cohen Y, Edelman R, Abbas R, Kurnik D, Shibel R, Livney YD, Enhancing the oral bioavailability of natural astaxanthin using plant-based micro- and nano-encapsulation materials: Results of an In vitro evaluation and a cross-over study in humans, Precision Nanomedicine 2020; 3 (4), 641-655.</citation>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Technion, Israel Institute of Technology</investigator_affiliation>
    <investigator_full_name>Yoav D. Livney</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Astaxanthin</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Encapsulation</keyword>
  <keyword>Potato protein</keyword>
  <keyword>Olive oil</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

